Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Potential synergy of cerebrospinal fluid TREM2 and BDNF/TrkB pathways promote mild depressive symptoms in Alzheimer’s disease through tau pathology

AI Summary
  • TREM2/sTREM2 neuroimmune dysfunction and impaired BDNF/TrkB signalling interact to exacerbate cognitive decline in preclinical Alzheimer's disease with mild depressive symptoms.
  • Reduced BDNF/TrkB signalling correlates with mild depressive symptoms and worse memory and executive function.
  • Tau pathology partly mediates the TREM2 and BDNF/TrkB interaction, linking neuroinflammation to accelerated cognitive impairment and informing early intervention.
Summarise with AI (MRCPsych/FRANZCP)

J Alzheimers Dis. 2026 Nov 14:13872877261503497. doi: 10.1177/13872877261503497. Online ahead of print.

ABSTRACT

BackgroundEarly identification of Alzheimer’s disease (AD) remains challenging. Mild depressive symptoms (MDSs) during the prodromal stage accelerate cognitive decline, but the underlying mechanisms remain unclear. Neuroinflammation and neurotrophic support are implicated in cognitive impairment, yet the interaction between triggering receptor expressed on myeloid cells 2 (TREM2)-mediated neuroimmune dysregulation and brain derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) deficits has not been established.ObjectiveThis study aimed to investigate whether alterations in cerebrospinal fluid (CSF) TREM2/sTREM2 and BDNF/TrkB interact to affect cognition in patients with AD and MDSs and whether tau pathology mediates this relationship, using observational data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).MethodsADNI data collected from 2005 to 2013 included 653 eligible participants. CSF TREM2, sTREM2, BDNF, TrkB, Aβ42, pTau181, and tTau levels, neuropsychiatric measures, and cognitive scores were analyzed using analysis of covariance, stratified analyses, mediation analyses, and multivariable linear regression adjusted for age, sex, education, and APOE ε4 status.ResultsCSF BDNF, TREM2, and sTREM2 levels varied significantly with age. sTREM2 appeared protective in early but not late disease stages. Reduced BDNF/TrkB signaling was associated with MDSs and poorer memory and executive function. Mediation analyses indicated that MDS-related cognitive impairment was partly mediated by TREM2/sTREM2-associated neuroinflammation and BDNF/TrkB dysfunction, particularly with elevated tau pathology.ConclusionsTREM2-mediated neuroimmune dysfunction and impaired BDNF/TrkB support may jointly exacerbate tau-related cognitive decline in preclinical AD with MDSs. This immune-neurotrophic interaction may promote dysfunctional microglial activation, excessive inflammation, and reduced clearance, offering a potential mechanism linking depressive symptoms to accelerated AD progression and informing early risk stratification and targeted intervention.

PMID:43033031 | DOI:10.1177/13872877261503497

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD